Analysis of prognostic factors in Grade 3 endometrioid type endometrial carcinoma

被引:2
作者
Sahin, Eda Adeviye [1 ]
Toprak, Serhat [2 ]
Sayal, Hasan Berkan [3 ]
Ekinci, Tekin [4 ]
Yilmaz, Ercan [5 ]
Bakay, Kadir [6 ]
Melekoglu, Rauf [5 ]
Sezgin, Burak [7 ]
Tohma, Yusuf Aytac [8 ]
Sahin, Hanifi [9 ]
机构
[1] Kolan Int Hosp, Dept Obstet & Gynecol, Istanbul, Turkey
[2] Inonu Univ, Fac Med, Dept Pathol, Malatya, Turkey
[3] Antalya Educ & Res Hosp, Dept Obstet & Gynecol, Antalya, Turkey
[4] Malatya Educ & Res Hosp, Dept Obstet & Gynecol, Malatya, Turkey
[5] Inonu Univ, Fac Med, Dept Obstet & Gynecol, Malatya, Turkey
[6] 19 Mayis Univ, Dept Obstet & Gynecol, Fac Med, Samsun, Turkey
[7] Mugla Sitki Kocman Univ, Fac Med, Dept Obstet & Gynecol, Mugla, Turkey
[8] Bahceci Hlth Grp, Dept Obstet & Gynecol, Ankara, Turkey
[9] Privata Clin, Dept Gynecol Oncol, Istanbul, Turkey
关键词
endometrial cancer; Grade3; prognostic factor; LYMPHOVASCULAR SPACE INVASION; CERVICAL STROMAL INVASION; LYMPH-NODE METASTASIS; RECURRENCE PATTERNS; HISTOLOGIC GRADE; SURVIVAL; CANCER; DIAGNOSIS; CA-125; DEPTH;
D O I
10.1002/ijgo.14277
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To investigate the prognostic factors of patients with Grade 3 endometrioid endometrial cancer (G3EEC). Methods This four-center, retrospective study included a total of 129 women with G3EEC. Demographic, clinicopathologic, and survival data were collected. Kaplan-Meier method was used for survival analysis. Predictors of outcome were analyzed using Cox proportional hazards models. Results Median age at the time of diagnosis was 63 (range 39-87) years and median follow up was 37 (range 6-126) months. For the entire cohort, the 5-year disease-free survival (DFS) and overall survival (OS) were 54.3% and 63.6%, respectively. The 5-year DFS rates for lymphovascular space invasion (LVSI) -positive and -negative patients were 41.6% and 88.3%, respectively (P < 0.001). The 5-year OS rates for LVSI-positive and -negative patients were 54.7% and 88.3%, respectively (P = 0.001). Positive LVSI status was identified as the independent prognostic factor for decreased DFS and OS (hazard ratio [HR] 5.5, 95% confidence interval [CI] 1.65-18.86; P = 0.006 versus HR 4.4, 95% CI 1.33-14.58; P = 0.013, respectively). Conclusion LVSI seems to be an independent prognostic factor for decreased DFS and OS in G3EEC patients.
引用
收藏
页码:719 / 726
页数:8
相关论文
共 21 条
  • [1] Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer
    Ayhan, Ali
    Sahin, Hanifi
    Sari, Mustafa Erkan
    Yalcin, Ibrahim
    Haberal, Ali
    Meydanli, Mehmet Mutlu
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (03) : 505 - 512
  • [2] Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer
    Bauer, Callie M. Cox
    Greer, Danielle M.
    Kram, Jessica J. F.
    Kamelle, Scott A.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 199 - 205
  • [3] ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up
    Colombo, Nicoletta
    Creutzberg, Carien
    Amant, Frederic
    Bosse, Tjalling
    Gonzalez-Martin, Antonio
    Ledermann, Jonathan
    Marth, Christian
    Nout, Remi
    Querleu, Denis
    Mirza, Mansoor Raza
    Sessa, Cristiana
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (01) : 2 - 30
  • [4] ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
    Concin, Nicole
    Matias-Guiu, Xavier
    Vergote, Ignace
    Cibula, David
    Mirza, Mansoor Raza
    Marnitz, Simone
    Ledermann, Jonathan
    Bosse, Tjalling
    Chargari, Cyrus
    Fagotti, Anna
    Fotopoulou, Christina
    Gonzalez Martin, Antonio
    Lax, Sigurd
    Lorusso, Domenica
    Marth, Christian
    Morice, Philippe
    Nout, Remi A.
    O'Donnell, Dearbhaile
    Querleu, Denis
    Raspollini, Maria Rosaria
    Sehouli, Jalid
    Sturdza, Alina
    Taylor, Alexandra
    Westermann, Anneke
    Wimberger, Pauline
    Colombo, Nicoletta
    Planchamp, Francois
    Creutzberg, Carien L.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 12 - 39
  • [5] Recurrent Endometrial Cancer
    Del Carmen, Marcela G.
    Boruta, David M., II
    Schorge, John O.
    [J]. CLINICAL OBSTETRICS AND GYNECOLOGY, 2011, 54 (02) : 266 - 277
  • [6] Cervical Stromal Invasion Predicting Survival in Endometrial Cancer
    Ferriss, J. Stuart
    Brix, William
    Tambouret, Rosemary
    DeSimone, Christopher P.
    Stoler, Mark
    Modesitt, Susan C.
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 116 (05) : 1035 - 1041
  • [7] Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer
    Knific, Tamara
    Osredkar, Josko
    Smrkolj, Spela
    Tonin, Irena
    Vouk, Katja
    Blejec, Andrej
    Grazio, Snjezana Frkovic
    Rizner, Tea Lanisnik
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 126 - 132
  • [8] Did GOG99 and PORTEC1 change clinical practice in the United States?
    Ko, Emily M.
    Funk, Michele Jonsson
    Clark, Leslie H.
    Brewster, Wendy R.
    [J]. GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 12 - 17
  • [9] Predicting Model of Lymph Node Metastasis Using Preoperative Tumor Grade, Transvaginal Ultrasound, and Serum CA-125 Level in Patients With Endometrial Cancer
    Lee, Jisun
    Kong, Tae-Wook
    Paek, Jiheum
    Chang, Suk-Joon
    Ryu, Hee-Sug
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (09) : 1630 - 1635
  • [10] Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer
    Matsuo, Koji
    Garcia-Sayre, Jocelyn
    Medeiros, Fabiola
    Casabar, Jennifer K.
    Machida, Hiroko
    Moeini, Aida
    Roman, Lynda D.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (06) : 669 - 676